Press Release

Date: 26th October 2026 National Stock Exchange of India BSE Limited Limited Exchange Plaza, C-1, Block G Phiroze Jeejeebhoy Towers Dalal Bandra Kurla Complex, Bandra (E), Street, Mumbai – 400001 Mumbai – 400051 Scrip Code: 544619 Scrip Symbol- SUDEEPPHRM Sub: FDA approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat. Dear Sir/Madam, This is to inform to the Exchange that, the Company has received FDA approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat. Press release is enclosed herewith. This is for your information and records. Sincerely, For Sudeep Pharma Limited Dimple Mehta Company Secretary & Compliance O(cid:431)icer M. No: F13184 ENCL: A/a CIN: L24231GJ1989PLC013141 Registered O(cid:431)ice: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India. Phone No.: +91 265 2840656, 7624095107 Corporate O(cid:431)ice: 601, 602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021, Gujarat, India Website: www.sudeeppharma.com, Email ID: mail@sudeepgroup.com Sudeep Pharma Limited FDA Approval Enables Commencement of Operations at New Pharma Greenfield Facility at 179 Nandesari, Gujarat  Received FDA approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat, authorising the commencement of manufacturing operations at the site.  The facility has an annual installed capacity of 51,200 MT, strengthening manufacturing capabilities across Pharma, Food & Nutrition and Specialty Ingredients.  Approval allows the Company to bring the new capacity on stream and serve growing demand from pharmaceutical, food and nutrition customers in domestic and international markets. Vadodara, October 26th, 2026: Sudeep Pharma Limited (NSE: SUDEEPPHRM, BSE: 544619), a leading manufacturer of pharmaceutical excipients, food and nutrition ingredients and specialty mineral-based solutions, today announced that its new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat, has received approval from the Gujarat Food and Drug Control Administration (FDA), authorising the Company to commence manufacturing operations at the site. The approval marks a significant milestone in the Company's growth journey and confirms that the facility's manufacturing systems, quality controls and compliance framework meet the requirements for commencing manufacturing operations. It reinforces the Company's commitment to strengthening manufacturing capabilities, quality standards and regulatory compliance. With an installed annual capacity of 51,200 MT, the facility represents an important addition to the Company's manufacturing infrastructure and will support its growing business requirements across domestic and international markets. Commercial supplies from this facility are expected to commence in H2 FY27, following the completion of customer qualification processes. Approximately 60% of the facility's capacity is allocated to the Company's existing Pharma, Food & Nutrition portfolio, while the remaining capacity will cater to newer product categories, including phosphates, glycinates, gluconates and citrates. The facility will also provide dedicated capacity for higher-value ingredients, reinforcing the Company's focus on portfolio diversification and strengthening its presence in regulated markets. Importantly, the additional capacity will enable the Company to manufacture new-age, high-value molecules such as bisglycinates, for which capacity at the existing mother plant was constrained. This will allow the Company to scale up production, cater to growing customer requirements and capitalise on emerging opportunities in specialised ingredients. Commenting on the development, Mr. Sujit Bhayani, Managing Director, Sudeep Pharma Limited, said: "The FDA approval for our 179 Nandesari greenfield facility marks an important milestone in our growth journey, enabling us to commence manufacturing operations and unlock significant additional capacity. It strengthens our ability to serve a wider customer base across pharmaceutical, food and nutrition segments in India and international markets. With the approval in place, we can now accelerate customer qualification processes and audits at the facility, facilitating the onboarding of both new and existing customers. The facility also provides us with the flexibility to expand our presence across existing and newer product categories, including high-value, specialised ingredients such as bisglycinates. This will enable us to address evolving customer requirements, scale up our specialised ingredients portfolio and pursue larger opportunities in international markets. We believe this investment will serve as an important growth driver as we progress into the next phase of our journey." About Sudeep Pharma Limited Sudeep Pharma Limited is a leading manufacturer of pharmaceutical excipients, food and nutrition ingredients and specialty mineral-based solutions, serving customers across India and international markets. With a strong foundation in mineral chemistry, manufacturing expertise and quality control, the Company offers a diversified portfolio of ingredients catering to pharmaceutical, food, nutrition and other specialised applications. The Company continues to expand its manufacturing capabilities, product portfolio and global presence, with a focus on innovation, value-added products and emerging growth opportunities, including battery materials through its subsidiary, Sudeep Advanced Materials. For more information, please contact: Company Details Investor Relations Advisors Sudeep Pharma Ltd. Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 CIN: L24231GJ1989PLC013141 Mr. Shrikant Sangani / Ms. Shaily Patwa Ms. Dimple Mehta – Company Secretary Email Id - shrikant.sangani@sgapl.net / shaily.p@sgapl.net Email Id – cs.sudeep@sudeepgroup.com Mobile No – 9619595686 / 9819494608 Telephone: +91 265 284 0656/329 1354 www.sgapl.net www.sudeeppharma.com DISCLAIMER: Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sudeep Pharma Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.